Also, similar to other anti-PD-1 therapies, NSCLC patients treated with budigalimab with high (≥ 50%) tumor PD-L1 expression had higher ORR (29%) compared with the overall NSCLC cohort or with NSCLC patients with confirmed ≥ 1% tumor PD-L1 expression (19% and 13% ORR, respectively) [23]. This evidence concerns the gene CD274 and neoplasm.